` TEVA (Teva Pharmaceutical Industries Ltd) vs Tel Aviv 355 Comparison - Alpha Spread

TEVA
vs
T
Tel Aviv 355

Over the past 12 months, TEVA has underperformed Tel Aviv 355, delivering a return of -8% compared to the Tel Aviv 355's +49% growth.

Stocks Performance
TEVA vs Tel Aviv 355

Loading
TEVA
Tel Aviv 355
Add Stock
www.alphaspread.com

Performance Gap
TEVA vs Tel Aviv 355

Loading
TEVA
Tel Aviv 355
Difference
www.alphaspread.com

Performance By Year
TEVA vs Tel Aviv 355

Loading
TEVA
Tel Aviv 355
Add Stock

Competitors Performance
Teva Pharmaceutical Industries Ltd vs Peers

Tel Aviv 355
TEVA
LLY
JNJ
NOVO B
ROG
Add Stock

Teva Pharmaceutical Industries Ltd
Glance View

Economic Moat
None
Market Cap
65.2B ILS
Industry
Pharmaceuticals

Teva Pharmaceutical Industries Ltd., a titan in the global pharmaceutical landscape, has navigated the intricate world of pharmaceuticals with a blend of strategic vision and operational efficiency. Founded in 1901 and headquartered in Israel, Teva has become synonymous with the production of affordable generic medications, a key pillar of its business model. The company's narrative is one of adaptability and foresight, having positioned itself as a leader in the generic drug sector by leveraging economies of scale and a vast distribution network. By acquiring and integrating smaller pharmaceutical firms over the years, Teva has expanded its portfolio to include a vast array of treatments that address a broad spectrum of therapeutic areas. This strategic expansion has enabled the company to offer nearly the same efficacy as brand-name drugs at a fraction of the cost, thus capturing significant market share and delivering value to both patients and healthcare systems worldwide. Beyond its prowess in generics, Teva has carved a niche in the specialty medicines market, focusing on innovative therapies that address complex conditions such as multiple sclerosis, migraine, and movement disorders. This dual-track approach to growth allows Teva to balance the volume-driven nature of the generics market with the higher margins offered by specialty drugs. The synthesis of these two facets – comprehensive generic offerings and targeted specialty pharmaceuticals – underpins Teva's revenue streams. Through a combination of robust pipeline development, strategic partnerships, and a commitment to operational excellence, Teva navigates the challenges of a competitive industry marked by ever-evolving regulations and pricing pressures, striving to maintain its status as a reliable provider of healthcare solutions on a global scale.

TEVA Intrinsic Value
5 358.02 ILS
Overvaluation 7%
Intrinsic Value
Price
Back to Top